2020/04/20

イナリサーチでは、新たな取り組みとして今年度よりオンラインセミナーの配信を開始しました。 お陰様で多くの反響を頂きました第5回の発表資料を公開いたします。 SENDの適用試験種にフォーカスし、初心者の方にもわかりやすい内容となっています。 お役立て頂ければ幸いです。（更新日：2020.4.20） イナリサーチ サイエンス・オンライン第5回（2020年4月16日配信） 「はじめてのSEND – 経験年数の少ない私だからお伝えできるSENDの基礎 -」 株式会社イナリサーチ　データ標準化推進部　小林 美紗

2020/03/26

SEND Support Services Ina Research offers comprehensive support services widely spreading from preparation of SEND data package to FDA application.  In cooperation with PDS LifeScience, a knowledgeable solution provider for SEND, we are constantly updating our services to respond changing requirements in a timely manner. Services Preparation of SEND data package (In-house/Contract studies) Quality check and verification of SEND data package As a Leading Company The highest risk to avoid is a loss of time and cost with are occurred in data rejection by FDA.  Since Ina Research has passed FDA trial application without any errors, continuously improving services and organization furthermore. Speed & Flexibility With flexiblity to meet various

2020/03/25

With the health safety and security of all stakeholders including employees and customers as our top priority, Ina Research (INA) has been implementing measures based on guidance received from government authorities in order to help prevent the spread of COVID-19 (SARS-CoV-2) infections. COVID-19 is the most urgent social concern in the world. However, comparing with European countries and US or China, the COVID-19 infection overshoot has not appeared in Japan as of today (March 25, 2020). Needless to say, we are never off our guard and protection to maintain all contracted studies in operation and all future studies. Animal Rooms: We, INA has highly advanced technologies such as One-by-One Animal

2019/12/03

Ina Research Co., Ltd. (hereinafter “the Company”) has decided today to enter into an agency contract with SAGE HEALTHCARE PTE LTD (hereinafter “SAGE”) in Singapore for the purpose of expanding sales of non-clinical studies focusing on pharmaceuticals. Information about entering into an agency contract with SAGE HEALTHCARE PTE LTD. – PDF (132KB)

2019/09/06

Ina Research Inc. (hereinafter referred to as “our company”) is pleased to announce that our company has decided to start the agency business for ViruSure (Austria : hereinafter referred to as “VS”), which is a contract research organization (hereinafter referred to as “CRO” ) in Japan and Taiwan today. (Please refer to the below PDF file for more details.) Announcement concerning the start of agency business with ViruSure GmbH (PDF: 128KB)

2019/08/07

Ina Research Inc. (INA) is pleased to announce the signing of an agency agreement with Level Biotechnology Inc. (LBI), a Taiwanese Contract Research Organization. 1.Market Potential The biopharmaceutical industry in Taiwan is currently growing at an unprecedented rate. With LBI as our locally-based agent, Taiwanese customers can now access INAs services in nonhuman primates, studies which are required as part of the biopharmaceutical development process. In this way, INA hopes to establish a mutually-complementary relationship with LBI, and make inroads into this growing market. 2. About LBI (1) Company Name: Level Biotechnology Inc. (2) Address: No. 80, Lane 169, Kangning St., His-Chih Dist., New Taipei City 221, Taiwan R.O.C. (3)

2019/07/08

A column regarding to the Grobal SEND Alliance (G-SEND) was posted on the website of Tokyo University AMED iD3 Catalyst Unit. G-SEND is a non-profit consortium, consisting of CROs from Japan, South Korea, Taiwan, Singapore, the US and Switzerland. They provide SEND data sets which are created in a standardized process and Ina Reseach is the central CRO as their base. Please see the link below for the article: http://www.id3catalyst.jp/e/column03.html

2019/03/29

Analysis Metabolism & Chemical Analysis INA offers analyses of test article and dosing formulations, as well as drug concentrations in biological samples. We also offer in vitro and in vivo analysis of hepatic drug-metabolizing enzymes and metabolizing enzyme gene expressions (mRNA). Analyses of drug concentrations in biological samples (TK, PK) ■Development of new analytical methodsNew analytical methods are developed by establishing the most favorable extraction method for the analysis of biological samples such as blood, urine, feces, and tissue homogenate (deproteinization, solid extraction or liquidliquid extraction). The optimal method to analyze the test article and its metabolites is then established, using either the preprocessing method, LC-MS/MS or HPLC systems. ■Validation

2019/03/29

Analysis Pathology At INA, necropsy and histotechnology are performed by well-trained technicians, and histopathological examinations are performed by certified toxicological pathologists, veterinary pathologists and toxicologists. Furthermore, we schedule regular in-house educational seminars, taught by our esteemed advisor of pathology. Pathology Necropsy Prompt and accurate postmortem examinations Perfusion fixation Specific fixation of organs/tissues Histotechnology Preparation of specimens for light microscopy (routine preparation, serial sections, large sections of the brain, etc.) Preparation of specimens for electron microscopy (TEM) Preparation of frozen sections (cryostat) Special staining (PAS, PAM, iron, Masson trichrome, Azan Maroly, Elastica Van Gieson, fat, etc.) Immunohistochemical staining (immunoenzymatic technique) Histopathology Examinations under light and electron microscopes General toxicity studies Specialty

2019/03/29

Clinical Pathology Clinical Pathology A wide range of clinical pathology services are available at INA, conducted by experienced veterinarians (certified clinical chemists) and medical technologists. Clinical Pathology Hematology Simultaneous evaluation of complete blood counts (red blood cell counts, white blood cell counts, platelet counts, hemoglobin and hematocrit measurements), white blood cell differential counts and reticulocyte counts/ratios using a hematoanalyzer). Microscopic measurement of reticulocytes by supravital staining and calculation of white blood cell differential (ratio) in blood smears. Blood coagulation/fibrinolysis Measurements of prothrombin time, activated partial thromboplastin time, fibrinogen and coagulation factor activities using a coagulator. D-dimer and fibrin/fibrinogen degradation product (FDP) measurements using commercial reagents. Measurement of platelet aggregation ability.